Upcoming Conference Schedules, Orphan Drug Designations and Stock Price Updates - Research Report on Pfizer, ICU Medical,

   Upcoming Conference Schedules, Orphan Drug Designations and Stock Price
Updates - Research Report on Pfizer, ICU Medical, CONMED, Gentium, and Repros
                                 Therapeutics

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 25, 2013

NEW YORK, November 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), ICU Medical, Inc. (NASDAQ: ICUI), CONMED Corporation
(NASDAQ: CNMD), Gentium S.p.A (NASDAQ: GENT), and Repros Therapeutics Inc.
(NASDAQ: RPRX). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Pfizer Inc. Research Report

On November 20, 2013, Pfizer Inc.'s (Pfizer) stock went up by 0.82% to $31.92
per share. However, over the previous three trading sessions, Pfizer's stock
went down 0.87%, compared to the S&P500 which went down by 0.93% during the
same trading period. The Full Research Report on Pfizer Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

ICU Medical, Inc. Research Report

On November 20, 2013, ICU Medical, Inc.'s (ICU Medical) stock closed at $63.21
per share, reflecting an increase of 3.32% over the previous day closing. Over
the past three trading day period, ICU Medical's stock went up by 1.17%,
compared to the Dow Jones Industrial Average which went down by 0.38% during
the same period. The Full Research Report on ICU Medical, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/be3b_ICUI

--

CONMED Corporation Research Report

On November 15, 2013, CONMED Corporation (CONMED) announced that the Company
will participate in the Piper Jaffray 25th Annual Healthcare Conference on
December 4, 2013, in New York City at 11:30 a.m. EST. According to CONMED, its
President and CEO, Mr. Joseph J. Corasanti will discuss the Company's
business, and the live webcast of the presentation will be made available on
its corporate website under the investors section. Also, the replay of the
same will be available through December 13, 2013 at the same location. The
Full Research Report on CONMED Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/a9b1_CNMD

--

Gentium S.p.A Research Report

On November 19, 2013, Gentium S.p.A (Gentium) announced that the European
Commission (EC) has granted Orphan Drug Designation to Defibrotide, the
Company's lead product candidate, for the prevention of Graft versus Host
Disease (GvHD). The Company stated that the designation follows a positive
opinion released by the Committee for Orphan Medicinal Products of the
European Medicines Agency, on October 10, 2013. Dr. Khalid Islam, Gentium
Chairman and CEO stated, "We are pleased to receive Orphan Drug Designation
for this second indication by the EMA for Defibrotide for the prevention of
GvHD. The granting of this Orphan Drug Designation is another important
milestone for Defibrotide as we continue our development of the product to
address significant unmet medical need for this potentially life-threatening
disease. We look forward to planning and initiating additional studies to
explore the full potential of Defibrotide in this indication." The Full
Research Report on Gentium S.p.A - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e100_GENT

--

Repros Therapeutics Inc. Research Report

On November 20, 2013, Repros Therapeutics Inc.'s (Repros Therapeutics) stock
was down 1.78%, closing the day at $14.33 per share. The Company's stock
declined 5.16% over the past three trading days, compared to the Nasdaq
composite which went down 1.62% during the same trading period. The Full
Research Report on Repros Therapeutics Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/2334_RPRX

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.

1.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
2.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
3.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
4.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
5.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.